Recombinant Human EPO protein

• Cat.No.: EPO-517H
• Product Overview: Recombinant Human EPO protein (Ala28-Arg193) carries no tag and was expressed in human 293 cells (HEK293).

Specification

• Species: Human
• Source: HEK293
• Protein Length: 166
• Description: Human Erythropoietin (EPO) is also known as EP, erythropoetin or erthropoyetin, and is a glycoprotein hormone that controls erythropoiesis, or red blood cell production. EPO is a cytokine for erythrocyte (red blood cell) precursors in the bone marrow. is synthesized by renal peritubular cells in adults, with a small amount being produced in the liver. Regulation is believed to rely on a feed-back mechanism measuring blood oxygenation. Constitutively synthesized transcription factors for EPO, known as hypoxia-inducible factors (HIFs), are hydroxylated and proteosomally digested in the presence of oxygen. It binds to the erythropoietin receptor (EpoR) on the red cell surface and activates a JAK2 cascade. Erythropoietin has its primary effect on red blood cells by promoting red blood cell survival through protecting these cells from apoptosis. It also cooperates with various growth factors involved in the development of precursor red cells. EPO has a range of actions including vasoconstriction-dependent hypertension, stimulating angiogenesis, and inducing proliferation of smooth muscle fibers. It has also been shown that erythropoietin can increase iron absorption by suppressing the hormone hepcidin. Erythropoietin has been shown to interact with the Erythropoietin receptor as its mechanism of action within the body. erythropoietin plays an important role in the brain's response to neuronal injury. EPO is also involved in the wound healing process.
• Form: Lyophilized from 0.22 um filtered solution in PBS, pH7.4, 10% trehalose.
• Molecular Mass: The protein has a calculated MW of 18.4 kDa. The protein migrates as 30-37 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
• Endotoxin: Less than 1.0 EU per ug by the LAL method.
• Purity: >97% as determined by SDS-PAGE.
• Storage: For long term storage, the product should be stored at lyophilized state at -20 centigrade or lower.
  Please avoid repeated freeze-thaw cycles.
  This product is stable after storage at:
  -20 centigrade to -70 centigrade for 12 months in lyophilized state;
  -70 centigrade for 3 months under sterile conditions after reconstitution.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4℃ before opening to recover the entire contents.

Gene Information

• Gene Name: EPO
• Official Symbol: EPO
• Synonyms: EPO; erythropoietin; EP; epoetin; MVCD2; MGC138142
• Gene ID: 2056
• mRNA Refseq: NM_000799
• Protein Refseq: NP_000790
• MIM: 133170
• UniProt ID: P01588

Citation

Hematologic safety of chronic brain-penetrating erythropoietin dosing in APP/PS1 mice

Journal: Alzheimer's & Dementia : Translational Research & Clinical Interventions    PubMed ID: 31660425    Data: 2019/10/17

Authors: Jiahong Sun, Joshua Yang, Rachita K. Sumbria

Article Snippet:cTfRMAb-EPO was produced in stably transfected Chinese hamster ovary cells cultured in serum-free medium and purified from conditioned medium by protein-G affinity chromatography [ ].cTfRMAb-EPO was produced in stably transfected Chinese hamster ovary cells cultured in serum-free medium and purified from conditioned medium by protein-G affinity chromatography [ ].. Both rhu-EPO (Creative BioMart) and cTfRMAb-EPO were formulated in 98 mM glycine, 148 mM NaCl, 28 mM Tris, 0.01% polysorbate 80, pH = 5.5, and stored at ?80°C.

Body and spleen weight changes after chronic treatment with cTfRMAb-EPO and rhu-EPO. Schematic of the injection and blood collection timeline (A). Panel A was created with BioRender.com . Mice were weighed weekly up to 8 weeks after treatment initiation. No significant difference was observed in the weight of the mice between the experimental groups (B). No significant difference in spleen weight was observed between the experimental groups (C). Data are presented as mean ± SEM of 7-11 mice per group. One-way ANOVA with Holm-Sidak's post hoc test was used to compare with WT-saline controls. Abbreviations: EPO, erythropoietin; WT, wild-type.

Red blood cell indices and platelet count of mice treated with saline, cTfRMAb-EPO, or rhu-EPO for 6 weeks followed by 2-week recovery period

Behavior analysis after chronic treatment with cTfRMAb-EPO and rhu-EPO. For the open-field (OF) test, the results at 6 weeks after treatment initiation were expressed as a percentage of baseline. rhu-EPO-treated APP/PS1 mice had significantly lower mean speed (A) and total distance (B) compared with WT-saline mice. Resting time in the APP/PS1-rhu-EPO mice was significantly higher than that in WT-saline mice (C). Time in the center was not significantly different between the experimental groups (D). Representative trajectories of saline-treated WT and saline-, cTfRMAb-EPO-, and rhu-EPO-treated APP/PS1 mice during the OF test (E). Composite memory z-scores for the recognition index during the NOR and % entries into novel arm during the Y-maze (F). Z-scores were significantly lower for APP/PS1-rhu-EPO mice and borderline significant for APP/PS1-saline mice. Data are presented as mean ± SEM of 7-11 mice per group. One-way ANOVA with Holm-Sidak's post hoc test was used to compare to the WT-saline controls for OF test, and one-sample t-test with a hypothesized mean = 0 for the z-score. ** P < .01. Abbreviations: EPO, erythropoietin; NOR, novel object recognition; WT, wild-type.